Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.6730
+0.0351 (5.50%)
At close: Sep 15, 2026, 4:00 PM EDT
0.6594
-0.0136 (-2.02%)
After-hours: Sep 15, 2026, 7:36 PM EDT
Outlook Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 11.24 | 8.08 | 14.93 | 23.39 | 17.4 | 14.48 |
Cash & Short-Term Investments | 11.24 | 8.08 | 14.93 | 23.39 | 17.4 | 14.48 |
Cash Growth | 26.30% | -45.85% | -36.19% | 34.46% | 20.17% | 15.49% |
Accounts Receivable | 1.64 | 1.49 | - | - | - | - |
Receivables | 1.64 | 1.49 | - | - | - | - |
Inventory | 5.04 | 3.34 | - | - | - | - |
Prepaid Expenses | 5.24 | 4.48 | 12.49 | 7.59 | 10.12 | 7.03 |
Total Current Assets | 23.17 | 17.39 | 27.42 | 30.98 | 27.52 | 21.51 |
Property, Plant & Equipment | 0.19 | 0.23 | 0.27 | 0.03 | 0.07 | 0.28 |
Long-Term Investments | 2.53 | 0.55 | 0.69 | 0.79 | 0.8 | 0.85 |
Long-Term Deferred Charges | - | 0.28 | - | - | 0.12 | - |
Other Long-Term Assets | 0.3 | 0.14 | 0.44 | 0.5 | 0.01 | 0.17 |
Total Assets | 26.18 | 18.58 | 28.82 | 32.3 | 28.53 | 22.81 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 6.81 | 10.19 | 7.97 | 6.57 | 3.49 | 2.2 |
Accrued Expenses | 3.28 | 5.31 | 3.24 | 2.75 | 3.43 | 1.73 |
Current Portion of Long-Term Debt | 18.23 | 29.95 | 29.44 | 35.55 | 10.92 | 0.9 |
Current Portion of Leases | 0.06 | 0.06 | 0.05 | 0 | 0.04 | 0.07 |
Current Income Taxes Payable | 0.3 | 0.3 | 1.86 | 1.86 | 1.86 | 1.86 |
Total Current Liabilities | 28.68 | 45.81 | 42.55 | 46.73 | 19.73 | 6.75 |
Long-Term Debt | - | - | - | - | - | 10.89 |
Long-Term Leases | 0.14 | 0.19 | 0.25 | - | 0 | 0.04 |
Other Long-Term Liabilities | 7.76 | 4.77 | 59.1 | 0.01 | 0.06 | 0.52 |
Total Liabilities | 36.58 | 50.77 | 101.9 | 46.74 | 19.79 | 18.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 1.87 | 0.54 | 0.24 | 0.13 | 2.27 | 1.76 |
Additional Paid-In Capital | 641.28 | 572.98 | 469.97 | 453.35 | 415.4 | 345.73 |
Retained Earnings | -653.54 | -605.71 | -543.28 | -467.92 | -408.94 | -342.88 |
Total Common Equity | -10.39 | -32.19 | -73.08 | -14.44 | 8.74 | 4.61 |
Shareholders' Equity | -10.39 | -32.19 | -73.08 | -14.44 | 8.74 | 4.61 |
Total Liabilities & Equity | 26.18 | 18.58 | 28.82 | 32.3 | 28.53 | 22.81 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 18.43 | 30.19 | 29.74 | 35.56 | 10.96 | 11.9 |
Net Cash (Debt) | -7.19 | -22.11 | -14.81 | -12.16 | 6.44 | 2.57 |
Net Cash Growth | - | - | - | - | 150.06% | -66.60% |
Net Cash Per Share | -0.09 | -0.64 | -0.80 | -0.97 | 0.61 | 0.34 |
Filing Date Shares Outstanding | 243.45 | 64.11 | 24.91 | 13.01 | 11.41 | 11.21 |
Total Common Shares Outstanding | 187.1 | 53.89 | 23.91 | 13.01 | 11.37 | 8.82 |
Working Capital | -5.51 | -28.43 | -15.14 | -15.75 | 7.79 | 14.76 |
Book Value Per Share | -0.06 | -0.60 | -3.06 | -1.11 | 0.77 | 0.52 |
Tangible Book Value | -10.39 | -32.19 | -73.08 | -14.44 | 8.74 | 4.61 |
Tangible Book Value Per Share | -0.06 | -0.60 | -3.06 | -1.11 | 0.77 | 0.52 |
Machinery | - | - | - | - | - | 1.07 |